阿尔茨海默病生物标志物阳性对神经心理网络的影响
Laura M Wright1, Matteo De Marco2, Cameron E Ferguson3
1School of Psychology, Faculty of Medical Sciences, Newcastle University, Newcastle-Upon-Tyne NE1 7RU, UK.
Brain communications
|February 12, 2026
概括
阿尔茨海默病 (AD) 生物标志物与改变的大脑网络有关,但不像预期的那样与情节性记忆有关. 语义记忆,特别是类别流性,在生物标志物阳性个体中显示出网络中心性的增加,这表明它在早期AD神经病理学中的支持作用.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 生物标志物研究 生物标志物研究
背景情况:
- 网络神经心理学为了解临床概况提供了一种新的方法.
- 阿尔茨海默病 (AD) 生物标志物与神经心理网络结构之间的关系尚不清楚.
- 情节性记忆通常是阿尔茨海默病中受影响的最早的认知领域.
研究的目的:
- 研究生物标志物阳性和生物标志物阴性个体之间神经心理网络结构的差异.
- 确定情节性记忆网络节点是否主要受到AD生物标志物的影响.
- 在AD神经病理学背景下探索语义记忆网络的作用.
主要方法:
- 来自国家阿尔茨海默氏症协调中心的大型队列的分析,使用统一数据集神经心理电池.
- 使用基于等级的相关性和LASSO惩罚计算神经心理残留和条件关联网络的构建.
- 使用基于 permutation 的模型,比较全球网络指标和粉样蛋白-阳性 (A+) 和粉样蛋白-阴性 (A-) 组,以及 A+T+和 A-T-组之间的节点中心性.
主要成果:
- 在生物标志物阳性和生物标志物阴性组之间观察到全球网络的度量差异.
- 与假设相反,在情节性记忆网络节点中没有发现显著差异.
- 在A+参与者中发现了类别流性 (语义记忆) 节点的中心性增加,在A+T+参与者中也有类似的趋势.
结论:
- 网络神经心理学在阿尔茨海默病研究中提供了超越传统单变量分析的补充见解.
- 虽然在阿尔茨海默病中出现了情节性记忆衰退,但它并没有反映在网络级异常中.
- 在患有AD生物标志物的个体中,语义记忆网络的变化是显著的,这表明潜在的补偿作用.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.4K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.7K
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
